source
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…BioSpace · 16d ago↗ source
- BMO sees Merck better positioned than BMS to handle looming patent cliffsBMO Capital Markets says Merck has a stronger plan than Bristol Myers Squibb to replace revenue lost to upcoming patent expirations. The firm highlights Merck's pipeline as more derisked and sizabl…
- Sarepta's Elevidys shows durable benefit in ambulatory Duchenne patients, analysts see turnaround potential